Misoprostol 25mcg Tablets

Misoprostol 25 mcg Tablets contain misoprostol, a synthetic prostaglandin E1 analogue that affects the uterus and cervix. Certain authorized low-dose tablet formulations are used to help initiate labour in pregnant patients when medically indicated.

Misoprostol promotes cervical ripening and uterine contractions. Its use for labour induction requires an appropriate obstetric assessment and monitoring of both the mother and baby.

The approved indication depends on the particular product and country. The 25 mcg labour-induction formulation should not be confused with other misoprostol tablet strengths or combination products.

Product Information

Product Name

Misoprostol 25 mcg Tablets

Active Ingredient

Misoprostol

Strength

25 micrograms per tablet

Dosage Form

Oral tablet, depending on the specific product

Drug Class

Prostaglandin E1 analogue

Therapeutic Category

Obstetric medicine

Use

Labour induction for authorized formulations

Product Reference

Angusta 25 microgram tablets in markets where authorized

Administration

Under the applicable product instructions and obstetric protocol

Pack Size

Verify the actual product packaging

Prescription Requirement

Subject to local regulations

Ordering and Availability

For Misoprostol 25 mcg tablet pricing, pack sizes and availability, contact the supplier to confirm the exact formulation, manufacturer, packaging and current stock.

Regulatory authorization, dispensing requirements and import eligibility vary by country. Verify that the specific product is authorized for the intended clinical use in the destination market before ordering.

Certain authorized misoprostol 25 mcg tablet products are used for:

• Labour Induction: Helps initiate uterine contractions when induction is medically indicated.
• Cervical Ripening: Helps prepare the cervix for labour.
• Obstetric Care: Provides a pharmaceutical option for labour induction under appropriate clinical supervision.

The suitability of misoprostol depends on the pregnancy, cervical assessment, obstetric history and applicable product authorization. It is not appropriate for every patient.

Misoprostol 25 mcg tablets must be administered according to the exact product label and the treating obstetric team's protocol.

The dose, administration interval and maximum amount depend on the authorized product and the patient's clinical circumstances. Do not use a general dosing schedule in place of the hospital's obstetric protocol.

This product must not be self-administered for labour induction. Administration requires trained obstetric personnel and access to monitoring of uterine contractions and fetal wellbeing.

Do not substitute a 25 mcg product with a 200 mcg tablet or another formulation without explicit clinical direction.

Storage Instructions

Store the tablets according to the manufacturer's instructions and the official product leaflet. Certain misoprostol tablets require protection from moisture and storage in their original packaging.

Check the expiry date and packaging before use. Do not use products that have expired, have damaged packaging or have been stored outside the specified conditions.

Possible adverse effects include:

• Nausea or vomiting
• Diarrhoea
• Abdominal pain
• Fever or chills
• Excessive or prolonged uterine contractions
• Changes in the baby's heart rate associated with uterine overstimulation

Serious complications can include uterine rupture, fetal distress and other severe obstetric emergencies.

The obstetric team should assess adverse symptoms and monitor the mother and baby during treatment.

Before administration, the obstetric team must review pregnancy history, previous uterine surgery, fetal presentation, placental position and other relevant clinical factors.

Important precautions include:

• Uterine overstimulation: Misoprostol can produce contractions that are too frequent, prolonged or strong.
• Previous uterine surgery: Certain products are contraindicated in patients with a uterine scar, including from a previous caesarean delivery.
• Fetal wellbeing: Assessment and monitoring are necessary according to the obstetric protocol.
• Other labour-induction medicines: Combining misoprostol with oxytocin or other uterotonic agents requires strict adherence to product-specific timing and contraindications.
• Pregnancy-related risks: The suitability of induction must be assessed by an obstetric professional.

The specific contraindications vary by product. Follow the official product leaflet and local hospital protocol.